Lung Cancer Therapeutics Report


The almost two thousand active oncology clinical trials paint a picture of an evolving therapeutic sector that has established players moving quickly to realize the expanded benefits of recent treatment protocols. One of the key therapeutic areas to advance has been the treatment and therapy for lung neoplasms and tumor proliferation pathways. This publication is one of several detailed and insightful decision tools that comprise Greystone’s Oncology Therapeutics practice.



The lung cancer therapeutics report is a comprehensive analysis of the rapidly evolving advances in this key area of oncology. A dozen targeted treatments, using novel pathways and signaling, have achieved results that represent a new era in oncology and antineoplastic therapeutics. There approaches have attracted a growing number of drug developers anxious to profit from therapies that can ease the physical, psychological and emotional burden of lung cancers. This report examines two dozen therapeutic drugs targeting lung cancer, and the biomarkers they utilize.